Enable JavaScript to ensure website accessibility
Precipio Regains Nasdaq Listing Compliance

NEW HAVEN, CT, (May 15, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on May [...]

Precipio Conducts IV-Cell™ Validation Trial With A Prominent Laboratory

NEW HAVEN, CT, (May 06, 2019) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it is [...]

Precipio Successfully Completes Nasdaq Hearing Process

Company is expected to regain listing compliance upon completion of the remaining 10-day requirement NEW [...]

Precipio Reminder Of Corporate Update Shareholder Call

Conference Call to be held Monday May 6th, 2019 at 5:00pm Eastern Time NEW HAVEN, [...]

Precipio Signs First Major International Services Contract

Contract expected to generate over $1.5M in revenues annually NEW HAVEN, CT, (April 29, 2019) – [...]

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Company announces 1-for-15 reverse stock split NEW HAVEN, CT, (April 26, 2019) – Specialty cancer diagnostics [...]

Precipio Launches Global Expansion Strategy

Precipio to capitalize on powerful data and expertise to grow business globally NEW HAVEN, CT, [...]

Mr. Ori Karev Joins Precipio Executive Team As Chief Strategy Officer

Precipio to expand its reach globally NEW HAVEN, CT, (April 18, 2019) – Specialty diagnostics company Precipio, [...]

Precipio Announces 2018 Year-End Corporate Update Call For Shareholders

Conference Call to Be Held On Monday, May 6th, 2019 at 5:00 PM ET NEW [...]

Precipio Identifies Manufacturer For Its IV-Cell Media

Manufacturing Partner enables Precipio to address customer demand and plans for global distribution NEW HAVEN, [...]